Obese people who engaged in resistance training were more likely to see reductions in a type of heart fat, a new study finds.
Amarin Corp. provided an update, noting that the company is increasing revenue guidance for 2019 and is planning to expand the sales force for Vascepa due to faster-than-expected growth.
Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. announced that Waylivra received conditional marketing authorization from the European Commission as the only therapy for FCS.
Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.
EU panel approves drug for rare genetic disease
Blood, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA), Familial Chylomicronemia Syndrome (FCS), Fat Accumulation, FDA, FDA/Regulatory, Inflammation, Pancreas, Platelet Count, Rare Genetic Diseases, Recommended For ApprovalAn advisory committee of the EMA recommended conditionally approving a drug from Akcea Therapeutics and Ionis Pharmaceuticals that aims to treat a rare genetic disease.